mRNA Development And Manufacturing Services

If you're evaluating contract development and manufacturing organizations (CDMOs) for mRNA programs, the co-location question matters more than most people realize. Transferring drug substance between sites for lipid nanoparticle (LNP) encapsulation and fill-finish introduces real risk, and it's one of the more underappreciated sources of project delay and batch failure.

Thermo Fisher Scientific's mRNA platform at Monza, Italy keeps plasmid production, in vitro transcription, RNA purification, LNP formation, and fill-finish under one roof. The CGMP-certified facility spans roughly 15,000 sq. ft., including a 10,800 sq. ft. manufacturing platform with up to five modular synthesis and purification suites and four LNP formulation areas. Scale runs from sub-gram early clinical work up to 100g batches, with annual capacity of 15 kg.

What's worth noting is the flexibility. You're not locked into a fixed bundle — the model lets you select core mRNA services and layer in upstream or downstream support where your program actually has gaps. Thirty-plus years of sterile injectables and biologics manufacturing experience backs the operation.